Boston Scientific

Chairman and CEO Mike Mahoney has over a decade of strong execution, sharpening focus on categories where Boston Scientific can be the go‑to platform and compounding through both internal innovation and smart M&A.

Leadership transitions are being managed deliberately, with long‑tenured finance leader Jon Monson succeeding CFO Dan Brennan in mid‑2025. Cultural emphasis on performance and values has translated into above‑market growth and sustained profitability expansion.

We view governance and strategic discipline favorably, noting the fast scaling of FARAPULSE, WATCHMAN, and the readiness to exit TAVR.